Sorrento Therapeutics Inc
NASDAQ:SRNE
Income Statement
Earnings Waterfall
Sorrento Therapeutics Inc
Revenue
|
62.8m
USD
|
Cost of Revenue
|
-33.5m
USD
|
Gross Profit
|
29.4m
USD
|
Operating Expenses
|
-344.8m
USD
|
Operating Income
|
-315.4m
USD
|
Other Expenses
|
-257.5m
USD
|
Net Income
|
-572.8m
USD
|
Income Statement
Sorrento Therapeutics Inc
Dec-2020 | Dec-2021 | Dec-2022 | ||
---|---|---|---|---|
Revenue | ||||
Revenue |
40
N/A
|
53
+32%
|
63
+19%
|
|
Gross Profit | ||||
Cost of Revenue |
(10)
|
(13)
|
(33)
|
|
Gross Profit |
30
N/A
|
40
+33%
|
29
-26%
|
|
Operating Income | ||||
Operating Expenses |
(275)
|
(441)
|
(345)
|
|
Selling, General & Administrative |
(116)
|
(197)
|
(182)
|
|
Research & Development |
(154)
|
(231)
|
(233)
|
|
Depreciation & Amortization |
(4)
|
(4)
|
(4)
|
|
Other Operating Expenses |
0
|
(9)
|
75
|
|
Operating Income |
(245)
N/A
|
(401)
-64%
|
(315)
+21%
|
|
Pre-Tax Income | ||||
Interest Income Expense |
(14)
|
(26)
|
(84)
|
|
Non-Reccuring Items |
(52)
|
(7)
|
(162)
|
|
Total Other Income |
0
|
(28)
|
0
|
|
Pre-Tax Income |
(311)
N/A
|
(463)
-49%
|
(562)
-21%
|
|
Net Income | ||||
Tax Provision |
2
|
34
|
2
|
|
Income from Continuing Operations |
(309)
|
(429)
|
(559)
|
|
Income to Minority Interest |
16
|
1
|
5
|
|
Equity Earnings Affiliates |
(6)
|
(0)
|
(18)
|
|
Net Income (Common) |
(298)
N/A
|
(428)
-44%
|
(573)
-34%
|
|
EPS (Diluted) |
-1.3
N/A
|
-1.45
-12%
|
-1.37
+6%
|